#USA #New Jersey #Class Action #Securities Fraud #ADMA Biologics

ADMA Biologics' Share Price Plummets Amidst Fraud Allegations

Recently, ADMA Biologics, Inc. has found itself at the center of controversy as allegations of securities fraud surfaced, resulting in a significant 29% drop in its stock value. A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP on behalf of investors, following reports of channel stuffing that potentially violated federal securities laws. This has not only affected investor confidence but also raised serious concerns regarding the transparency of ADMA’s financial practices.

Background of the Allegations

ADMA, a company engaged in the biopharmaceutical industry, specializes in the development and marketing of specialty biologics, including its flagship product, ASCENIV. This liquid immune globulin solution is essential for treating Primary Humoral Immunodeficiency in children and adults. The turmoil began when Culper Research, an investigative firm, released a report alleging that ADMA inflated its reported growth figures through dubious practices, specifically channel stuffing, which involves inducing distributors to acquire excess inventory.

According to the report, ADMA allegedly provided incentives to one of its distributors, including extended payment terms and rebates, to stockpile ASCENIV, thereby creating an illusion of increased demand. This deceptive strategy may have led investors to believe that the company was enjoying a robust 20% growth in revenues for 2025 when, in fact, the reality was a decline of approximately 3%. Such discrepancies indicate a significant breach not only of ethical standards but potentially also of federal regulations governing securities reporting.

Impact on Stock Prices

The ramifications of these allegations were immediate and severe. On March 24, 2026, ADMA’s stock saw a staggering decline of approximately $2.26, or 16.6%, dipping from a previous close of $13.59 to $11.33 per share. The following day did not show any signs of recovery, as the stock further plummeted to $9.63, reflecting an additional drop of 15%. Industry analysts suggest that the subsequent downgrading by Cantor on concerns derived from the initial report only accelerated the downward trend, resulting in losses across the market for ADMA shares.

Legal Actions and Investor Options

In light of these developments, the U.S. District Court for the District of New Jersey is currently overseeing the class action case titled _Mazzarino v. ADMA Biologics, Inc., et al._ Investors who feel they have been wronged are being encouraged to act swiftly, as the deadline to join the lead plaintiff in the case is set for August 10, 2026. The class action seeks to address potential violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

For those affected by the drop in ADMA’s stock, BFA Law assures potential clients that there are no upfront costs associated with representation; fees will only be pursued following successful litigation outcomes. Thus, investors may find themselves with viable options for recouping losses incurred as a result of alleged fraud.

Conclusion

ADMA Biologics stands on shaky ground as it navigates the fallout from these allegations. With a once-promising stock trajectory now marred by serious legal challenges, investors are left grappling with concerns regarding accountability and corporate governance in the biopharmaceutical space. As this case unfolds, it will not only impact ADMA’s future but could also set important precedents in the regulatory landscape surrounding securities and investor protections. Prospective plaintiffs are urged to stay informed and consider their legal options as developments emerge.